Australia's Radiopharm Theranostics jumps on receiving U.S. FDA approval

Radiopharm Theranostics

30/12/2022 24:35

** Shares of Australia's Radiopharm Theranostics Ltd
 RAD.AX  rise as much as 5% to A$0.105, set to mark their best
day since Dec. 22, if gains hold 
    ** Radiopharmaceutical product maker says it has received
U.S. FDA Investigational New Drug Application approval for its
αVβ6 Integrin (RAD301) technology 
    ** αVβ6 Integrin (RAD301) is used to treat pancreatic cancer
    ** Co says it is now proceeding with clinical site
preparation for the trial
    ** Stock has fallen 73.8% this year, as of last close
 (Reporting by Nausheen Thusoo in Bengaluru)
 ((Nausheen.Thusoo@thomsonreuters.com;))